CME accredited course focussed on the role of PCSK9 inhibitors in the management of patients at increased CV risk. Member registration (free) is needed to enroll in this course

PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

PCSK9: Outcomes and trials in clinical perspective There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. Prof. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines.

PCSK9: Outcomes and trials in clinical perspective Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

PCSK9: Outcomes and trials in clinical perspective Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.